Skip to main content
NCBI home page
Gut logoLink to Gut
. 1975 Nov;16(11):876–883. doi: 10.1136/gut.16.11.876

Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.

W H Summerskill, M G Korman, H V Ammon, A H Baggenstoss
PMCID: PMC1413126  PMID: 1104411

Abstract

Among 120 consecutive patients with chronic active liver disease (CALD) randomized to different treatments, those receiving maintenance doses of prednisone 20 mg daily (Pred), prednisone in doses given on alternate days and titrated to secure resolution of clinical and biochemical abnormalities (Pred-Titrad), or a combination of prednisone 10 mg and azathioprine 50 mg daily (Comb) survived and underwent resolution of clinical and biochemical features of disease more often than a control group receiving placebo or azathioprine 100 mg daily. Histological remission occurred significantly more often with Pred and Comb than with other regimens. Major side-effects of therapy were commoner with Pred than with Comb or Pred-Titrad, which did not differ. We conclude that Comb is the initial treatment of choice for CALD, since clinical, biochemical, and histological resolution of disease activity occurs as often as with Pred, whereas early side-effects are significantly less frequent.

Full text

PDF
876

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baggenstoss A. H., Soloway R. D., Summerskill W. H., Elveback L. R., Schoenfield L. J. Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol. 1972 Jun;3(2):183–198. doi: 10.1016/s0046-8177(72)80072-8. [DOI] [PubMed] [Google Scholar]
  2. Becker M. D., Baptista A., Scheuer P. J., Sherlock S. Prognosis of chronic persistent hepatitis. Lancet. 1970 Jan 10;1(7637):53–57. doi: 10.1016/s0140-6736(70)91843-x. [DOI] [PubMed] [Google Scholar]
  3. Cook G. C., Mulligan R., Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971 Apr;40(158):159–185. doi: 10.1093/oxfordjournals.qjmed.a067264. [DOI] [PubMed] [Google Scholar]
  4. Geall M. G., Schoenfield L. J., Summerskill W. H. Classification and treatment of chronic active liver disease. Gastroenterology. 1968 Dec;55(6):724–729. [PubMed] [Google Scholar]
  5. HARTER J. G., REDDY W. J., THORN G. W. STUDIES ON AN INTERMITTENT CORTICOSTEROID DOSAGE REGIMEN. N Engl J Med. 1963 Sep 19;269:591–596. doi: 10.1056/NEJM196309192691201. [DOI] [PubMed] [Google Scholar]
  6. Mackay I. R. Chronic hepatitis: effect of prolonged suppressive treatment and comparison of azathioprine with prednisolone. Q J Med. 1968 Jul;37(147):379–392. [PubMed] [Google Scholar]
  7. Mistilis S. P., Blackburn C. R. The treatment of active chronic hepatitis with 6-mercaptopurine and azathioprine. Australas Ann Med. 1967 Nov;16(4):305–311. doi: 10.1111/imj.1967.16.4.305. [DOI] [PubMed] [Google Scholar]
  8. Mistilis S. P. Natural history of active chronic hepatitis. II. Pathology, pathogenesis and clinico-pathological correlation. Australas Ann Med. 1968 Nov;17(4):277–288. doi: 10.1111/imj.1968.17.4.277. [DOI] [PubMed] [Google Scholar]
  9. Mistilis S. P., Skyring A. P., Blackburn C. R. Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality and survival. Australas Ann Med. 1968 Aug;17(3):214–223. doi: 10.1111/imj.1968.17.3.214. [DOI] [PubMed] [Google Scholar]
  10. Murray-Lyon I. M., Stern R. B., Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1973 Apr 7;1(7806):735–737. doi: 10.1016/s0140-6736(73)92125-9. [DOI] [PubMed] [Google Scholar]
  11. Page A. R., Good R. A., Pollara B. Long-term results of therapy in patients with chronic liver disease associated with hypergammaglobulinemia. Am J Med. 1969 Nov;47(5):765–774. doi: 10.1016/0002-9343(69)90169-7. [DOI] [PubMed] [Google Scholar]
  12. Penn I., Starzl T. E. Malignant tumors arising de novo in immunosuppressed organ transplant recipients. Transplantation. 1972 Oct;14(4):407–417. doi: 10.1097/00007890-197210000-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Siegel R. R., Luke R. G., Hellebusch A. A. Reduction of toxicity of corticosteroid therapy after renal transplantation. Am J Med. 1972 Aug;53(2):159–169. doi: 10.1016/0002-9343(72)90126-x. [DOI] [PubMed] [Google Scholar]
  14. Soloway R. D., Baggenstoss A. H., Schoenfield L. J., Summerskill W. H. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis. 1971 Dec;16(12):1082–1086. doi: 10.1007/BF02235164. [DOI] [PubMed] [Google Scholar]
  15. Soloway R. D., Summerskill W. H., Baggenstoss A. H., Geall M. G., Gitnićk G. L., Elveback I. R., Schoenfield L. J. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972 Nov;63(5):820–833. [PubMed] [Google Scholar]
  16. Summerskill W. H. Chronic active liver disease reexamined: prognosis hopeful. Gastroenterology. 1974 Mar;66(3):450–464. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES